14 June 2021 - NICE will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by the companies and various charities.

Kyowa Kirin, Lymphoma Action and Leukaemia Care as well as the UK Cutaneous Lymphoma Group lodged the appeal after NICE rejected Poteligeo (mogamulizumab) in a final appraisal document earlier this year.

Read Pharma Times article